Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Recruiting

OmegavenSafety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment

Sponsor:

Fresenius Kabi

Code:

NCT06274788

Conditions

Parenteral Nutrition Associated Liver Disease (PNALD)

Essential Fatty Acid Deficiency

Malnutrition

Pediatric ALL

Eligibility Criteria

Sex: All

Age: 0 - 17

Healthy Volunteers: Not accepted

Interventions

Omegaven® (fish oil triglycerides) Injectable Emulsion

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-12. This information was provided to ClinicalTrials.gov by Fresenius Kabi on 2025-09-05.